{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:11:10Z","timestamp":1792714270976,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004955","name":"\u00d6sterreichische Forschungsf\u00f6rderungsgesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoantibody-associated demyelinating diseases of the central nervous system such as myelin oligodendrocyte glycoprotein-antibody associated disease (MOGAD) and aquaporin 4-antibody positive neuromyelitis optica spectrum disorders (AQP4+ NMOSD) are rare diseases but can cause severe disability. In both diseases, associated neuroinflammation is accompanied by blood and cerebrospinal fluid cytokine and chemokine signatures, which were shown to be distinct from those observed in patients with multiple sclerosis (MS). In this study, we aimed to confirm and extend these findings by analyzing a larger number of serum cytokines, chemokines and related molecules in patients with MOGAD or AQP4+ NMOSD in comparison to MS, to better understand the pathophysiology and to identify biomarkers potentially useful in clinical practice for diagnostic and treatment purposes. A total of 65 serum cytokines, chemokines and related molecules like growth factors and soluble receptors were measured by Procartaplex multiplex immunoassays in 40 MOGAD, 40 AQP4+ NMOSD and 54 MS patients at baseline. Furthermore, follow-up samples of 25 AQP4+ NMOSD and 40 MOGAD patients were measured after 6-12 months. Selected analytes were validated in a subgroup of samples using other bead-based assays and ELISA. At baseline, 36 analytes in MOGAD and 30 in AQP4+ NMOSD were significantly increased compared to MS. K-means cluster analysis of all significantly altered molecules revealed three distinct groups: Cluster I, including 12 MOGAD, 2 AQP4+ NMOSD and 3 MS patients, had a specific association with 11 IL-6\/IL-17A associated cytokines. In this cluster, 9\/17 (53%) patients were children. Cluster II with 13 MOGAD, 24 AQP4+ NMOSD and 1 MS patient was associated with 31 upregulated analytes. Cluster III contained 15 MOGAD, 14 AQP4+ NMOSD and 50 MS patients. In cluster II and III the majority were adults (82% and 92%). Most measured analytes remained stable over time. Validation of selected cytokines and chemokines using other analytical methods revealed moderate to high correlation coefficients, but absolute values differed between assays. In conclusion, these results obtained by bead-based multiplex assays highlight a significant association of biomarkers of peripheral inflammation in patients with antibody-associated demyelinating diseases in comparison with MS.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1037812","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T07:09:57Z","timestamp":1668409797000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder"],"prefix":"10.3389","volume":"13","author":[{"given":"Angelika","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Rudzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Berek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Dinoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Wendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"H\u00f6ftberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Rostasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mariotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Reindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-Associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflamm"},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1471-2377-12-95","article-title":"TH1\/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate or natalizumab","volume":"12","author":"Oreja-Guevara","year":"2012","journal-title":"BMC Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2055217319848463","DOI":"10.1177\/2055217319848463","article-title":"Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases","volume":"5","author":"Hofer","year":"2019","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: A cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cyto.a.22348","article-title":"T Helper cells plasticity in inflammation","volume":"85","author":"Cosmi","year":"2014","journal-title":"Cytometry A"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1038\/s41467-020-16625-7","article-title":"Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica","volume":"11","author":"Agasing","year":"2020","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-Associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol - Neuroimmunology Neuroinflamm"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010455","article-title":"Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica","volume":"5","author":"Mader","year":"2010","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: Appropriate use and interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth Analg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149411","article-title":"B cell, Th17, and neutrophil related cerebrospinal fluid Cytokine\/Chemokines are elevated in MOG antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2011.01.031","article-title":"Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse","volume":"18","author":"Wang","year":"2011","journal-title":"J Clin Neurosci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9709-9","article-title":"Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse","volume":"32","author":"Wang","year":"2012","journal-title":"J Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"Matsushita","year":"2013","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000494976","article-title":"Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: Significance of interleukin-6","volume":"25","author":"Wei","year":"2018","journal-title":"Neuroimmunomodulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"577925","DOI":"10.1016\/j.jneuroim.2022.577925","article-title":"IL-6 as a marker for NMOSD disease activity","volume":"370","author":"Haramati","year":"2022","journal-title":"J Neuroimmunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4137\/BMI.S35005","article-title":"Patterns of local and systemic cytokines in bacterial meningitis and its relation with severity and long-term sequelae","volume":"10","author":"Perdomo-Celis","year":"2015","journal-title":"biomark Insights"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161656","article-title":"Utility of CSF Cytokine\/Chemokines as markers of active intrathecal inflammation: Comparison of demyelinating, anti-NMDAR and enteroviral encephalitis","volume":"11","author":"Kothur","year":"2016","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms7110514","article-title":"Inflammatory immune responses in patients with tick-borne encephalitis: Dynamics and association with the outcome of the disease","volume":"7","author":"Bogovi\u010d","year":"2019","journal-title":"Microorganisms"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23198","article-title":"Cytokine characteristic of cerebrospinal fluid from children with enteroviral meningitis compared to bacterial meningitis","volume":"34","author":"Xu","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2086070","article-title":"Comparison of laboratory and immune characteristics of the initial and second phase of tick-borne encephalitis","volume":"11","author":"Bogovi\u010d","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2021.02.002","article-title":"Cerebrospinal fluid type I interferon and cytokine profiles in enteroviral meningitis according to the presence or absence of pleocytosis","volume":"62","author":"Lee","year":"2021","journal-title":"Pediatr Neonatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003222","article-title":"Clinical value of assessing cytokine levels for the differential diagnosis of bacterial meningitis in a pediatric population","volume":"95","author":"Ye","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/1354750X.2020.1714737","article-title":"Investigating the role of T helper related cytokines in cerebrospinal fluid for the differential diagnosis of bacterial meningitis in pre-treated paediatric patients","volume":"25","author":"Jafari","year":"2020","journal-title":"Biomarkers"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24140","article-title":"Analysis of serum levels of cytokines, chemokines, growth factors, and monoamine neurotransmitters in patients with tick-borne encephalitis: Identification of novel inflammatory markers with implications for pathogenesis","volume":"87","author":"Palus","year":"2015","journal-title":"J Med Virol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/0883073816653780","article-title":"Cytokine and chemokine expression in CSF may differentiate viral and autoimmune NMDAR encephalitis in children","volume":"31","author":"Ygberg","year":"2016","journal-title":"J Child Neurol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0947","article-title":"Diagnostic usefulness of cytokine and chemokine levels in the cerebrospinal fluid of patients with suspected tuberculous meningitis","volume":"101","author":"Kwon","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2021.01.010","article-title":"Serum cytokine profile of pediatric patients with laboratory confirmed pneumococcal meningitis","volume":"14","author":"Zheng","year":"2021","journal-title":"J Infect Public Health"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181449","article-title":"Elevations of novel cytokines in bacterial meningitis in infants","volume":"13","author":"Srinivasan","year":"2018","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S185336","article-title":"Cytokines and chemokines expression in serum of patients with neuromyelitis optica","volume":"15","author":"Ai","year":"2019","journal-title":"NDT"},{"key":"B45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1471-2172-10-52","article-title":"Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays","volume":"10","author":"Jager","year":"2009","journal-title":"BMC Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20021","article-title":"Multiplex bead array assays for detection of soluble cytokines: Comparisons of sensitivity and quantitative values among kits from multiple manufacturers","volume":"61","author":"Khan","year":"2004","journal-title":"Cytometry B Clin Cytom"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2011.09.025","article-title":"Multiplex assays of inflammatory markers, a description of methods and discussion of precautions - our experience through the last ten years","volume":"56","author":"Skogstrand","year":"2012","journal-title":"Methods"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.99","article-title":"Changes in b- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis","volume":"67","author":"Piccio","year":"2010","journal-title":"Arch Neurol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12699","article-title":"The interplay between mast cells, pineal gland, and circadian rhythm: Links between histamine, melatonin, and inflammatory mediators","volume":"70","author":"Pham","year":"2021","journal-title":"J Pineal Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1037812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T07:09:59Z","timestamp":1668409799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1037812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2022.1037812"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1037812","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"article-number":"1037812"}}